Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)

S. Chandrakala; Manoj Toshniwal; Mitesh Halvawala; Namita Padwal; Neeraj Sidharthan; Pankaj Malhotra; B. Prashantha; Riya Ballikar; Sandip Shah; Shashikant Apte; T. Kasi Viswanathan; Vijay Ramanan; Akhilesh Sharma; Dattatray Pawar; Roshan Pawar; Vinayaka Shahavi

doi:10.1007/s12288-023-01635-4

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)

S. Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B. Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T. Kasi Viswanathan, Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar, Vinayaka Shahavi

Department of General Medicine, Kasturba Medical College, Mangalore

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article “Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia” written by S. Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B. Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T. Kasi Viswanathan,Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar and Vinayaka Shahavi was originally published without Open Access.After online publication, the author decided to opt forOpen Choice and to make the article an Open Access publication.Therefore,

Original language	English
Journal	Indian Journal of Hematology and Blood Transfusion
DOIs	https://doi.org/10.1007/s12288-023-01635-4
Publication status	Accepted/In press - 2023

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s12288-023-01635-4

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)'. Together they form a unique fingerprint.

Cite this

Chandrakala, S., Toshniwal, M., Halvawala, M., Padwal, N., Sidharthan, N., Malhotra, P., Prashantha, B., Ballikar, R., Shah, S., Apte, S., Viswanathan, T. K., Ramanan, V., Sharma, A., Pawar, D., Pawar, R., & Shahavi, V. (Accepted/In press). Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5). Indian Journal of Hematology and Blood Transfusion. https://doi.org/10.1007/s12288-023-01635-4

@article{77b11c9e511345f8a78934ca07cc5fec,

title = "Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)",

abstract = "The article “Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia” written by S. Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B. Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T. Kasi Viswanathan,Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar and Vinayaka Shahavi was originally published without Open Access.After online publication, the author decided to opt forOpen Choice and to make the article an Open Access publication.Therefore,",

author = "S. Chandrakala and Manoj Toshniwal and Mitesh Halvawala and Namita Padwal and Neeraj Sidharthan and Pankaj Malhotra and B. Prashantha and Riya Ballikar and Sandip Shah and Shashikant Apte and Viswanathan, {T. Kasi} and Vijay Ramanan and Akhilesh Sharma and Dattatray Pawar and Roshan Pawar and Vinayaka Shahavi",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s).",

year = "2023",

doi = "10.1007/s12288-023-01635-4",

language = "English",

journal = "Indian Journal of Hematology and Blood Transfusion",

issn = "0971-4502",

publisher = "Springer India",

}

Chandrakala, S, Toshniwal, M, Halvawala, M, Padwal, N, Sidharthan, N, Malhotra, P, Prashantha, B, Ballikar, R, Shah, S, Apte, S, Viswanathan, TK, Ramanan, V, Sharma, A, Pawar, D, Pawar, R & Shahavi, V 2023, 'Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)', Indian Journal of Hematology and Blood Transfusion. https://doi.org/10.1007/s12288-023-01635-4

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5). / Chandrakala, S.; Toshniwal, Manoj; Halvawala, Mitesh et al.
In: Indian Journal of Hematology and Blood Transfusion, 2023.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)

AU - Chandrakala, S.

AU - Toshniwal, Manoj

AU - Halvawala, Mitesh

AU - Padwal, Namita

AU - Sidharthan, Neeraj

AU - Malhotra, Pankaj

AU - Prashantha, B.

AU - Ballikar, Riya

AU - Shah, Sandip

AU - Apte, Shashikant

AU - Viswanathan, T. Kasi

AU - Ramanan, Vijay

AU - Sharma, Akhilesh

AU - Pawar, Dattatray

AU - Pawar, Roshan

AU - Shahavi, Vinayaka

PY - 2023

Y1 - 2023

N2 - The article “Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia” written by S. Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B. Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T. Kasi Viswanathan,Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar and Vinayaka Shahavi was originally published without Open Access.After online publication, the author decided to opt forOpen Choice and to make the article an Open Access publication.Therefore,

AB - The article “Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia” written by S. Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B. Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T. Kasi Viswanathan,Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar and Vinayaka Shahavi was originally published without Open Access.After online publication, the author decided to opt forOpen Choice and to make the article an Open Access publication.Therefore,

UR - http://www.scopus.com/inward/record.url?scp=85148957358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148957358&partnerID=8YFLogxK

U2 - 10.1007/s12288-023-01635-4

DO - 10.1007/s12288-023-01635-4

M3 - Comment/debate

AN - SCOPUS:85148957358

SN - 0971-4502

JO - Indian Journal of Hematology and Blood Transfusion

JF - Indian Journal of Hematology and Blood Transfusion

ER -

Chandrakala S, Toshniwal M, Halvawala M, Padwal N, Sidharthan N, Malhotra P et al. Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5). Indian Journal of Hematology and Blood Transfusion. 2023. doi: 10.1007/s12288-023-01635-4

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia (Indian Journal of Hematology and Blood Transfusion, (2022), 10.1007/s12288-022-01602-5)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this